Multiple types of resistance to new lung cancer drug identified

May 4, 2015
Lung CA seen on CXR. Credit: James Heilman, MD/Wikipedia

After identifying three different types of resistance to a promising investigational lung cancer drug in a phase 1 trial, a team of researchers led by Dana-Farber Cancer Institute scientists say new targeted inhibitors and combinations are urgently needed to stay ahead of tumors' constant and varied molecular shape-shifting.

The researchers, including scientists from pharmaceutical company AstraZeneca, report in an advanced online publication in Nature Medicine on May 4, that their findings indicate "an underappreciated genomic heterogeneity" in mechanisms of resistance to tyrosine kinase inhibitor (TKI) drugs that target the Epidermal Growth Factor Receptor (EGFR) mutation that drive some cases of non-small cell lung cancer (NSCLC).

"If resistance that is this complex is constantly evolving before us, it may mean we need multiple targeted therapies in combination to stay ahead of the resistant cancer," said Geoffrey Oxnard, MD, a thoracic oncologist and lung cancer researcher at Dana-Farber and senior author of the report.

Since the initial discovery of EGFR mutations in lung cancer 10 years ago, EGFR targeted therapies such as erlotinib (Tarceva) and afatinib (Gilotrif) have become a fundamental component of therapy. Though they can induce dramatic responses, they tend to lose their effectiveness after nine to 14 months of treatment because of the development of resistance. The most common cause of drug resistance is the development of a second EGFR mutation known as T790-M.

To fight back, pharmaceutical companies are developing and testing next-generation inhibitors aimed at overcoming the T790-M resistance mutation. One such drug, the AstraZeneca compound AZD9291, is showing promise against resistant NSCLC in the ongoing phase 1 AURA clinical trial. In the April 30 issue of the New England Journal of Medicine, Dana-Farber's Pasi Jänne, MD, PhD, and colleagues reported that AZD9291 shrank lung tumors in 61 percent of patients whose cancers had developed the T790-M resistance mutation. The median progression-free survival in these patients was 10 months.

In the new Nature Medicine study, Oxnard and colleagues looked for mechanisms of resistance to AZD9291 by analyzing liquid biopsies from some of the first patients in the clinical trial whose disease progressed despite treatment with the drug. In effect, they were spying on the cancer's next strategy for evading the new drug.

Rather than wait for tumor biopsy samples to become available, scientists captured "cell-free" DNA shed into the bloodstream by the tumor cells. Oxnard, working with researchers from the Belfer Institute for Applied Cancer Science at Dana-Farber, had recently developed an assay to detect and quantify EGFR mutations in cell-free DNA. By testing blood specimens at different times during treatment, the scientists identified that three subtypes of resistance emerged.

In some patients, the cancer cells carrying the T790-M mutation acquired an additional EGFR mutation not seen before, labeled C797S, which blocked the AZD9291 from docking to the tumor cells, and causing the disease to advance. In some other patients, the drug failed to eliminate cells with the T790-M resistance mutation—but the C797S mutation was not the culprit. In still other patients, the cancer cells progressed, but the AZD9291 appeared to have eliminated the T790-M resistance mutation, suggesting some other resistance mechanism had taken control. The findings "highlight the need for novel strategies to inhibit EGFR even in the presence of this [C797S] mutation," the authors said. That might mean designing new drugs that block the effect of the mutation.

While EGFR inhibitors have lengthened lives and improved outcomes in patients with advanced NSCLC, experience has shown that inevitably develops. "The quicker we can learn about , the faster we can overcome it," said Oxnard. He said the new study demonstrates the power of liquid biopsies of resistant cancers to identify the biological causes and—in the present case—report those mechanisms simultaneously with the publication of the clinical trial results for a new drug.

Explore further: Two new lung cancer meds show promise in advanced disease

More information: Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M, DOI: 10.1038/nm.3854

Related Stories

Two new lung cancer meds show promise in advanced disease

April 30, 2015
(HealthDay)—Two experimental drugs may help patients whose lung cancer has become resistant to the latest available treatments, according to separate studies published in the April 30 issue of the New England Journal of ...

Team reports promising results of phase 1/2 trial of rociletinib in EGFR lung cancer

April 29, 2015
The New England Journal of Medicine reports results of a multi-center phase I/II study of the investigational anti-cancer agent rociletinib (CO-1686) in patients with EGFR-mutant non-small cell lung cancer (NSCLC) that had ...

Potential new drug for some patients with treatment-resistant lung cancer

October 20, 2013
The investigational drug AZD9291, a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors, ...

Dual therapy's 1-2 punch knocks out drug-resistant lung cancer

April 2, 2015
Capitalizing on a rare opportunity to thoroughly analyze a tumor from a lung cancer patient who had developed resistance to targeted drug treatment, UC San Francisco scientists identified a biological escape hatch that explains ...

Blood samples as surrogates for tumor biopsies in patients with lung cancer

February 26, 2015
A study examined the feasibility of using circulating free DNA (cfDNA) from blood samples of patients with advanced non-small-cell lung cancer as a surrogate for tumor biopsies to determine tumor-causing epidermal growth ...

Not all EGFR mutations are the same when it comes to therapy for non-small cell lung cancer

February 10, 2015
Certain rare epidermal growth factor receptor (EGFR) mutations are associated with tobacco smoking, worse prognosis and poor response to EGFR tyrosine kinase inhibitor (TKI) therapy compared to the more common "classical" ...

Recommended for you

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

Computer program finds new uses for old drugs

November 16, 2017
Researchers at the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, ...

Pharmacoscopy improves therapy for relapsed blood cancer in a first clinical trial

November 16, 2017
Researchers at CeMM and the Medical University of Vienna presented a preliminary report in The Lancet Hematology on the clinical impact of an integrated ex vivo approach called pharmacoscopy. The procedures measure single-cell ...

Wider sampling of tumor tissues may guide drug choice, improve outcomes

November 15, 2017
A new study focused on describing genetic variations within a primary tumor, differences between the primary and a metastatic branch of that tumor, and additional diversity found in tumor DNA in the blood stream could help ...

A new strategy for prevention of liver cancer development

November 14, 2017
Primary liver cancer is now the second leading cause of cancer-related death worldwide, and its incidences and mortality are increasing rapidly in the United Stated. In late stages of the malignancy, there are no effective ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.